Ovarian cancer frequently acquires resistance to platinum chemotherapy, representing a major challenge for improving patient survival. Recent work suggests that resistant clones exist within a larger drug-sensitive cell population prior to chemotherapy, implying that resistance is selected for rather than generated by treatment. We sought to compare clinically derived, intrapatient paired model...

BACKGROUND Platinum-based agents are widely used in chemotherapy against solid tumors and insufficient intracellular drug accumulation is one of the leading causes of platinum resistance which is associated with poor survival of tumor patients. Thus, the detection of intracellular platinum is pivotal for studies aiming to overcome platinum resistance. In the present study, we aimed to establish...

Ovarian carcinoma (OC) is the most lethal gynecological malignancy. Despite the advances in the treatment of OC with combinatorial regimens, including surgery and platinum-based chemotherapy, patients generally exhibit poor prognosis due to high chemotherapy resistance. Herein, we tested the hypothesis that DNA damage response (DDR) pathways are involved in resistance of OC patients to platinum...

Platinum-based chemoradiotherapy (CRT) is a standard front-line treatment for locally advanced non-small cell lung cancer (NSCLC). However, no clinical trials have compared the efficacy and toxicity of platinum combination and docetaxel as subsequent re-challenge chemotherapies after cancer recurrence following CRT. This study aimed to evaluate the efficacy and toxicity of platinum combination ...

Three murine leukemia lines resistant to cÃo-diamminedichloroplatinum(II) and one line resistant to diaminocyclohexane (DACH) platinum(II) complexes were compared to their platinum-sensitive parent lines to determine whether differences in net platinum accumulation were related to the resistant phenotype. The ciVdiamminedichloroplatinum(II}-resistant lines (L1210PIR4, L1210DDPS, P388PtR4) and t...

The objectives of this study were to assess the pharmacokinetics and safety of subcutaneously delivered carboplatin in poloxamer 407 in rats. Carboplatin (5mg/rat) in 0.5ml poloxamer 407 (1.0 ml total volume) was administered subcutaneously in a right subcutaneous perineal incision in all 12 treatment rats. Three control rats received 1.0 ml of poloxamer 407. Total platinum was measured in plas...

Reactions of Complexes of Platinum Metals with Bio-Molecules Water Soluble Rhodium Catalysts The Destruction of Polychlorinated Biphenyls Chemical Conversion of Carbon Dioxide The Electrodeposition of Platinum and Platinum Alloys Ruthenium in Cancer Chemotherapy Lean-Burn Oxygen Sensor Material Control of Corrosion in Molten Carbonate Fuel Cells Flammable Gas Detection International Congress on...

Forty microampere current was generated on a platinum-titanium dioxide Schottky diode during the platinum catalyzed steady-state oxidation of carbon monoxide at 80 degrees C. For reaction events that produced four CO(2) molecules, three injected electrons were collected in a diode comprising a 5 nm thick platinum and a 150 nm titanium dioxide film. The electron injection flux depends on the thi...

Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum a...